TCD601 for Kidney Transplantation

Around 30,000 people are given a kidney transplant each year in the United States. This accounts for 6% of U.S. kidney transplantation. Most organs are placed to help patients who have either severe or lifetime complications stemming from CKD. However, 20% of patients get a kidney transplant due to severe complications or imminent death. Most patients are unaware that they are receiving a kidney transplant. Most patients undergoing kidney transplantation do so because their renal function has deteriorated to the point where their CKD is incompatible with their quality of life.

The study results show that [kidney transplant](https://www.withpower.com/clinical-tri[als](https://www.withpower.com/clinical-trials/als)/kidney-transplant)ation is effective in preventing and reversing a wide range of kidney diseases, which include proteinuria and hypertension in most cases. This treatment method was also efficient in preventing and reversing chronic kidney disease, even when implemented for several years afterwards.

Although a cure cannot be obtained for either chronic kidney disease or a kidney allograft, the possibility of cure can be raised if the disease is treated aggressively and effectively prior to and during transplantation.

The main causes of death in kidney transplant recipients are infectious and cardiovascular diseases, lung diseases, and cancers. It is important to screen patients for these signs.

In this review we looked at the history of Kidney Transplantation and discuss various parts of the medical field. We have discussed how the first successful kidney transplant was performed on 6 April 1968 at the Boston's Peter Bent Brigham Hospital and also the first deceased donor kidney transplant was performed on 24 July 1968 by Dr. E. E. Boylan at the University Hospital of Pennsylvania, Philadelphia. Currently in 2012, according to the American Association for the Renal Registry, more than 4.5 million living kidney transplants and more than one million deceased kidney transplants were performed.

The current literature reveals a diverse range of common treatments for kidney transplantation, from corticosteroids and anticytokines to newer agents such as cell-based therapies. The treatment protocol depends on the nature and type of kidney disease. More studies need to be conducted to develop the most efficient treatment for kidney transplantation.

The average age at transplantation in U.S. transplants has risen considerably over time. Older patients may be undertreated, especially for frail patients. The increased utilization of cadaveric allograft is a result of demographic changes, but it also means that waiting times increase with age at transplantation. In the future, improving patient selection of high-quality donors with use of the [Power, Simeon, et al.] tool will ensure better patient care.

Diabetes is the most common cause of kidney transplantation among young to middle-aged adults, while viral hepatitis and chronic kidney disease are more frequent causes among elderly adults. Diabetes or viral hepatitis are the main causes of kidney transplantation among children.

At the end of the study subjects receiving Tcd601 showed more improvement of the histological and endoscopic score, as well as reduction in both CRP levels and serum interleukin-8 levels, compared with patients receiving a placebo. These data suggested that Tcd601 was a better medication than a placebo. However, the follow-up examinations will be conducted to find the long-term impact of Tcd601 on the outcome of patients with duodenal ulcer.

Tcd601 is an orally bioavailable peptidomic lead with activity against tuberculosis. Tcd601 is a novel inhibitor of the cell wall synthesis system of M. tuberculosis. These studies provide the basis for the development of oral and injectable therapeutics against Mycobacterium tuberculosis. The combination of a potent, oral bismuth-containing compound with an investigational small-molecule peptidomic antagonist offers a novel approach for treatment of M. tuberculosis.

Tcd601 is a novel, orally available, small molecule drug and demonstrates strong preclinical activity against the human mycobacterial protein MmpIIA and the human neutrophil protease elastase, key bacterial proteases found to be functionally active in chronic granulomatous disease. Results from a recent clinical trial suggest an important therapeutic role of Tcd301 in granulomatous and autoimmune conditions. Further clinical development of the drug is now being initiated. Tcd601 has an estimated potency of approximately 18,000-fold (10,000 times) over standard antiseptic drugs and is thus far the strongest known anti-PDE4-based drug with significant therapeutic potential.